ERBB2 and breast carcinoma: Similarly, a phase 2 study showed little benefit with pertuzumab [11] for the treatment of patients with HER2-low breast cancer, and a retrospective analysis looking at trastuzumab-emtansine (T-DM1) in HER2-non-amplified tumors found little activity.